A Phase 2 interventional study of AZD2281 and matching placebo in Ovarian Cancer, sponsored by AstraZeneca. Completed at 107 sites in 17 countries. Open to female participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2025-02-03.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies testing olaparib in Ovarian Neoplasms — 13 open to participants now, 26 under way, 9 of them phase 3. olaparib · Ovarian Neoplasms.
Among the 69 studies testing olaparib in Ovarian Neoplasms, this one is the 15th largest by enrollment, is one of 4 that started in 2008, is one of 32 in phase 2, and was the 6th registered.
3,390 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.
Browse Ovarian Neoplasms studies →13 of the 69 studies testing olaparib in Ovarian Neoplasms are open now, in 8 countries. Recruiting first, the newest first:
Bai-Rong Xia · Sites in China
Ages 18–75 · Women only
Daewoong Pharmaceutical Co. LTD. · Sites in Korea, Republic of
Ages 19+ · Women only
Boryung Pharmaceutical Co., Ltd · Sites in Korea, Republic of
Ages 19–74 · Women only
The Netherlands Cancer Institute · Sites in Netherlands
Ages 18–100 · Women only
NRG Oncology · Sites in United States, Japan, Puerto Rico
Ages 18+
By country, each count listing its studies:
olaparib: first FDA approval 2014 (LYNPARZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 602 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.
This study: 18 Years to 130 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, olaparib is the treatment under test here. Read study by study →
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 35 · Phase 3 17 · Phase 4 3
First in 2005; this study’s year is marked. 4 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 265 is above the median of 54 across 2,556 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 96 across the 69 interventional studies. Of the 33 that completed or were terminated, 16 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 69 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
70 studies in Ovarian Neoplasms by AstraZeneca: 8 open now, 20 under way, 6 of them phase 3. Of 45 finished, 15 (33%) have results posted.
Among the 70 studies in Ovarian Neoplasms by AstraZeneca, this one is the 16th largest by enrollment of the 47 interventional ones that give a count, is one of 4 that started in 2008, is one of 12 in phase 2, and was the 9th registered.
AstraZeneca’s Ovarian Neoplasms studies by the year they started, since 2001.
5 of the studies testing olaparib in Ovarian Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04421963Phase 3AstraZenecaRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib | 2027-04-06 |
| NCT03579316M.D. Anderson Cancer CenterAdavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | 2026-12-31 |
| NCT07371104Daewoong Pharmaceutical Co. LTD.Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer | 2027-03 |
| NCT07460180The Netherlands Cancer InstituteThe PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian Cancer | 2027-05-01 |
| NCT03943173M.D. Anderson Cancer CenterOlaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery | 2027-06-27 |
Add all 5 to your calendar (.ics) → With an account.
Among the 69 studies testing olaparib in Ovarian Neoplasms, from their registry updates:
Among AstraZeneca’s 70 in Ovarian Neoplasms:
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study to determine if AZD2281 is effective and well tolerated in maintaining the improvement in your cancer after previous platinum-based chemotherapy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AZD2281
Drug: AZD2281
matching placebo
Drug: matching placebo
Tablets Oral BID
Also known as: Olaparib, Lynparza
matching placebo bid
Progression Free Survival (PFS) (According to Response Evaluation Criteria in Solid Tumours [RECIST])
PFS was defined as the time from randomisation to the earlier date of radiological progression (per RECIST criteria) or death by any cause in the absence of objective progression. \[Full analysis set (FAS)\]
Time frame: Radiologic scans performed at baseline then every 12 weeks (+/- 1 week) for the first 60 weeks, then every 24 weeks (+/-1 week) thereafter, assessed maximum up to 14 months.
Overall Survival (OS)
OS = time from randomisation to date of death from any cause. Patients who had not died at time of analysis were censored at last date patient was known to be alive.
Time frame: Follow up every 12 weeks post progression, assessed maximum up to 90 months.
Objective Response Rate (ORR) (According to RECIST)
For each treatment group, the ORR was the number of Complete Response (CR) and Partial Response (PR) divided by the number of patients in the group in the FAS with measurable disease at baseline (displayed as a percentage below). Evaluable for response set
Time frame: Radiologic scans performed at baseline then every 12 weeks (+/- 1 week) for the first 60 weeks, then every 24 weeks (+/-1 week) thereafter, assessed maximum up to 14 months.
Disease Control Rate
Disease control rate was defined as the percentage of patients who have at least 1 confirmed visit response of CR or PR or have demonstrated SD or NED for at least 23 weeks (ie, 24 weeks +/- 1 week) prior to any evidence of progression. \[FAS\]
Time frame: Assessed at 24 weeks. Radiologic scans performed at baseline, week 12 (+/- 1 week) and week 24 (+/- 1 week).
Duration of Response
Duration of response = time from assessment prior to timepoint where PR or CR confirmed (i.e. initial assessment of PR/CR), until earliest date of objective progression or death. \[Responding patients only\]. There were insufficient responses to enable conclusions to be drawn.
Time frame: Radiologic scans performed at baseline then every 12 weeks (+/- 1 week) for the first 60 weeks, then every 24 weeks (+/-1 week) thereafter, assessed maximum up to 14 months.
Percentage Change From Baseline in Tumour Size at Week 24
Percentage change from baseline to Week 24 in target tumour size.
Time frame: Radiologic scans performed at baseline then every 12 weeks (+/- 1week) for the first 60 weeks, then every 24 weeks (+/-1 week) thereafter, assessed maximum up to 14 months.
Best Percentage Change in Cancer Antigen 125 (CA-125) Levels
Best percentage change from baseline in CA-125 level
Time frame: CA-125 was measured at baseline then every 28 days on treatment, assessed maximum up to 14 months.
Best Objective Response
Best overall response from radiologic assessments. \[FAS\]
Time frame: Radiologic scans performed at baseline then every 12 weeks (+/- 1week) for the first 60 weeks, then every 24 weeks (+/- 1 week) thereafter, assessed maximum up to 14 months.
RECIST and CA-125 Response Separately and Combined
RECIST and CA-125 response separately and combined \[Patients evaluable for either CA-125 response or RECIST response\]
Time frame: Radiologic scans performed at baseline then every 12 weeks (+/- 1week) for the first 60 weeks, then every 24 weeks (+/- 1 week) thereafter and monthly for CA-125 measurements, assessed maximum up to 14 months.
Time to Earlier of CA-125 or RECIST Progression
Time from randomisation to the earlier date of radiological progression (per RECIST criteria) or CA-125 or death by any cause in the absence of objective progression. \[FAS\]
Time frame: Radiologic scans performed at baseline then every 12 weeks (+/- 1 week) for the first 60 weeks, then every 24 weeks (+/- 1 week) thereafter and monthly for CA-125 measurements, assessed maximum up to 14 months.
Improvement Rate for FACT-O Symptom Index (FOSI)
The percentage of patients with an improvement in FOSI. Improvement was defined as a change from baseline of greater than or equal to +3. \[Evaluable for FOSI set\]
Time frame: Patient reported outcome questionnaire completed at baseline then every 28 days up to disease progression, assessed maximum up to 14 months.
Improvement Rate for Trial Outcome Index (TOI)
The percentage of patients with an improvement in TOI. Improvement was defined as a change from baseline of greater than or equal to +7. \[Evaluable for TOI set\]
Time frame: Patient reported outcome questionnaire completed at baseline then every 28 days up to disease progression, assessed maximum up to 14 months.
Improvement Rate for Total Functional Analysis of Cancer Therapy - Ovarian (FACT-O)
The percentage of patients with an improvement in total FACT-O. Improvement was defined as a change from baseline of greater than or equal to +9. \[Evaluable for FACT-O set\]
Time frame: Patient reported outcome questionnaire completed at baseline then every 28 days up to disease progression, assessed maximum up to 14 months.
FACT-O Symptom Index (FOSI) Time to Worsening
The time to worsening was compared between treatments for each of the TOI, FOSI and total FACT-O. \[Evaluable for FOSI set\]
Time frame: Patient reported outcome questionnaire completed at baseline then every 28 days up to disease progression, assessed maximum up to 14 months.
Trial Outcome Index(TOI)Time to Worsening
The time to worsening was compared between treatments for each of the TOI, FOSI and total FACT-O. \[Evaluable for TOI set\]
Time frame: Patient reported outcome questionnaire completed at baseline then every 28 days up to disease progression, assessed maximum up to 14 months.
Functional Analysis of Cancer Therapy - Ovarian (FACT-O) Time to Worsening
The time to worsening was compared between treatments for each of the TOI, FOSI and total FACT-O. \[Evaluable for FACT-O set\]
Time frame: Patient reported outcome questionnaire completed at baseline then every 28 days up to disease progression, assessed maximum up to 14 months.
The first patient was enrolled on 28 August 2008 and the last patient was enrolled on 9 February 2010. Patients were enrolled at 82 centres in 16 countries. Of the 326 patients enrolled, 265 were randomized
| Milestone | Olaparib 400 mg bd | Placebo bd |
|---|---|---|
| Started | 136 | 129 |
| Completed | 28 | 11 |
| Not completed | 108 | 118 |
| Withdrew: Death | 98 | 112 |
| Withdrew: Lost to follow-up | 2 | 3 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Voluntary discontinuation of patient | 7 | 3 |
PFS was defined as the time from randomisation to the earlier date of radiological progression (per RECIST criteria) or death by any cause in the absence of objective progression. \[Full analysis set (FAS)\]
| Months | Olaparib 400 mg bd | Placebo bd |
|---|---|---|
| Progression Free Survival (PFS) (According to Response Evaluation Criteria in Solid Tumours [RECIST]) | 8.4 (7.4 to 11.5) | 4.8 (4.0 to 5.5) |
OS = time from randomisation to date of death from any cause. Patients who had not died at time of analysis were censored at last date patient was known to be alive.
| Months | Olaparib 400 mg bd | Placebo bd |
|---|---|---|
| Overall Survival (OS) | 29.8 (26.9 to 35.7) | 27.8 (24.9 to 33.7) |
For each treatment group, the ORR was the number of Complete Response (CR) and Partial Response (PR) divided by the number of patients in the group in the FAS with measurable disease at baseline (displayed as a percentage below). Evaluable for response set
| percentage of participants | Olaparib 400 mg bd | Placebo bd |
|---|---|---|
| Objective Response Rate (ORR) (According to RECIST) | 12.3 | 4.2 |
Disease control rate was defined as the percentage of patients who have at least 1 confirmed visit response of CR or PR or have demonstrated SD or NED for at least 23 weeks (ie, 24 weeks +/- 1 week) prior to any evidence of progression. \[FAS\]
| percentage of participants | Olaparib 400 mg bd | Placebo bd |
|---|---|---|
| Disease Control Rate | 53.7 | 25.6 |
Duration of response = time from assessment prior to timepoint where PR or CR confirmed (i.e. initial assessment of PR/CR), until earliest date of objective progression or death. \[Responding patients only\]. There were insufficient responses to enable conclusions to be drawn.
| Months | Olaparib 400 mg bd | Placebo bd |
|---|---|---|
| Duration of Response | 4.2 (2.8 to 5.6) | 2.3 (1.8 to 2.8) |
Percentage change from baseline to Week 24 in target tumour size.
| Percent change in tumour size | Olaparib 400 mg bd | Placebo bd |
|---|---|---|
| Percentage Change From Baseline in Tumour Size at Week 24 | -0.8 (-100.0 to 45.0) | 26.4 (-36.4 to 39.4) |
Best percentage change from baseline in CA-125 level
| percentage of change | Olaparib 400 mg bd | Placebo bd |
|---|---|---|
| Best Percentage Change in Cancer Antigen 125 (CA-125) Levels | -16.67 (-100.00 to 346.15) | 0.00 (-99.50 to 1436.84) |
Best overall response from radiologic assessments. \[FAS\]
| Participants | Olaparib 400 mg bd | Placebo bd |
|---|---|---|
| Complete Response | 0 | 0 |
| Partial Response | 7 | 2 |
| No evidence of disease | 49 | 42 |
| Stable Disease >= 11 weeks | 46 | 25 |
| Disease Progression | 24 | 55 |
| Not Evaluable | 10 | 5 |
RECIST and CA-125 response separately and combined \[Patients evaluable for either CA-125 response or RECIST response\]
| Participants | Olaparib 400 mg bd | Placebo bd |
|---|---|---|
| RECIST Response | 16 | 2 |
| Confirmed RECIST Response | 7 | 2 |
| Unconfirmed RECIST response | 9 | 0 |
| CA-125 Response | 1 | 1 |
| Confirmed RECIST or CA-125 Response | 8 | 3 |
Time from randomisation to the earlier date of radiological progression (per RECIST criteria) or CA-125 or death by any cause in the absence of objective progression. \[FAS\]
| Months | Olaparib 400 mg bd | Placebo bd |
|---|---|---|
| Time to Earlier of CA-125 or RECIST Progression | 8.3 (5.5 to 10.3) | 3.7 (2.8 to 4.5) |
The percentage of patients with an improvement in FOSI. Improvement was defined as a change from baseline of greater than or equal to +3. \[Evaluable for FOSI set\]
| percentage of evaluable participants | Olaparib 400 mg bd | Placebo bd |
|---|---|---|
| Improvement Rate for FACT-O Symptom Index (FOSI) | 17.1 | 14.8 |
The percentage of patients with an improvement in TOI. Improvement was defined as a change from baseline of greater than or equal to +7. \[Evaluable for TOI set\]
| percentage of evaluable participants | Olaparib 400 mg bd | Placebo bd |
|---|---|---|
| Improvement Rate for Trial Outcome Index (TOI) | 20.0 | 18.0 |
The percentage of patients with an improvement in total FACT-O. Improvement was defined as a change from baseline of greater than or equal to +9. \[Evaluable for FACT-O set\]
| percentage of evaluable participants | Olaparib 400 mg bd | Placebo bd |
|---|---|---|
| Improvement Rate for Total Functional Analysis of Cancer Therapy - Ovarian (FACT-O) | 21.1 | 18.9 |
The time to worsening was compared between treatments for each of the TOI, FOSI and total FACT-O. \[Evaluable for FOSI set\]
| Months | Olaparib 400 mg bd | Placebo bd |
|---|---|---|
| FACT-O Symptom Index (FOSI) Time to Worsening | 2.8 (1.8 to 3.7) | 3.7 (3.3 to 5.6) |
The time to worsening was compared between treatments for each of the TOI, FOSI and total FACT-O. \[Evaluable for TOI set\]
| Months | Olaparib 400 mg bd | Placebo bd |
|---|---|---|
| Trial Outcome Index(TOI)Time to Worsening | 3.8 (2.8 to 7.4) | 4.6 (3.7 to 7.4) |
The time to worsening was compared between treatments for each of the TOI, FOSI and total FACT-O. \[Evaluable for FACT-O set\]
| Months | Olaparib 400 mg bd | Placebo bd |
|---|---|---|
| Functional Analysis of Cancer Therapy - Ovarian (FACT-O) Time to Worsening | 2.8 (1.9 to 4.7) | 4.6 (3.6 to 5.5) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Olaparib 400 mg bd | — | 31/136 (22.8%) | 129/136 (94.9%) |
| Placebo | — | 11/128 (8.6%) | 111/128 (86.7%) |
| Event | Olaparib 400 mg bd | Placebo |
|---|---|---|
| SMALL INTESTINAL OBSTRUCTIONGastrointestinal disorders | 2/136 | 3/128 |
| ANAEMIABlood and lymphatic system disorders | 3/136 | 0/128 |
| GASTRITISGastrointestinal disorders | 0/136 | 2/128 |
| PANCYTOPENIABlood and lymphatic system disorders | 2/136 | 0/128 |
| CONSTIPATIONGastrointestinal disorders | 2/136 | 0/128 |
| FEMUR FRACTUREInjury, poisoning and procedural complications | 2/136 | 0/128 |
| DYSPNOEARespiratory, thoracic and mediastinal disorders | 2/136 | 0/128 |
| ABDOMINAL PAINGastrointestinal disorders | 0/136 | 1/128 |
| IMPAIRED GASTRIC EMPTYINGGastrointestinal disorders | 0/136 | 1/128 |
| INTESTINAL OBSTRUCTIONGastrointestinal disorders | 1/136 | 1/128 |
| Event | Olaparib 400 mg bd | Placebo |
|---|---|---|
| NAUSEAGastrointestinal disorders | 96/136 | 46/128 |
| FATIGUEGeneral disorders | 73/136 | 50/128 |
| VOMITINGGastrointestinal disorders | 47/136 | 18/128 |
| ABDOMINAL PAINGastrointestinal disorders | 35/136 | 34/128 |
| DIARRHOEAGastrointestinal disorders | 36/136 | 31/128 |
| CONSTIPATIONGastrointestinal disorders | 30/136 | 14/128 |
| DECREASED APPETITEMetabolism and nutrition disorders | 29/136 | 17/128 |
| HEADACHENervous system disorders | 29/136 | 17/128 |
| DYSPEPSIAGastrointestinal disorders | 27/136 | 11/128 |
| ANAEMIABlood and lymphatic system disorders | 26/136 | 7/128 |
| Age, Continuous(years) | Olaparib 400 mg bd | Placebo bd | Total |
|---|---|---|---|
| Mean | 58.9 ± 10.95 | 58.5 ± 9.89 | 58.7 ± 10.43 |
| Sex: Female, Male(Participants) | Olaparib 400 mg bd | Placebo bd | Total |
|---|---|---|---|
| Female | 136 | 129 | 265 |
| Male | 0 | 0 | 0 |
| Time to progression(participants) | Olaparib 400 mg bd | Placebo bd | Total |
|---|---|---|---|
| >6 to 12 months | 53 | 54 | 107 |
| >12 months | 83 | 75 | 158 |
| Objective response(Participants) | Olaparib 400 mg bd | Placebo bd | Total |
|---|---|---|---|
| Complete response | 57 | 63 | 120 |
| Partial response | 79 | 66 | 145 |
Showing the first 100 of 107 sites across 17 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Aug 2008 to primary completion in Jun 2010, 22 months.
Results were first posted in Mar 2013, 2 years 8 months after primary completion.
Of 116 industry-sponsored phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 51. This study's 22 months is below that.
Counting every sponsor, half of 344 studies reached it within 47 months; a quarter within 33 and three quarters within 72.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olaparib